|
|
|
|
|
|||||||
|
Session 4
Oral Abstract Session
Antiretroviral Chemotherapy: New Agents Monday, 10 am - 12:30 pm 6A-B |
| Moderators | Mary Albrecht, Beth Israel Deaconess Med. Ctr., Boston, MA and Stefano Vella, Inst. Superiore Di Sanita, Rome,
Italy | ||
| 10:00 1. | SCH C: Safety and Antiviral Effects of a CCR5 Receptor Antagonist in HIV-1- Infected Subjects J. Reynes1, R. Rouzier2, T. Kanouni2, V. Baillat2, B. Baroudy3, A. Keung3, C. Hogan4, M. Markowitz4, and M. Laughlin*3 1Univ. Hosp., Montpellier, France; 2Ctr. CAP, Montpellier, France; 3Schering Plough Res. Inst., Kenilworth, NJ; and 4Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY
| ||
| 10:15 2. | AMD-3100, a CXCR4 Antagonist, Reduced HIV Viral Load and X4 Virus Levels in Humans D. Schols*1, S. Claes1, E. De Clercq1, C. Hendrix2, G. Bridger3, G. Calandra3, G. Henson3, S. Fransen4, W. Huang4, J. M. Whitcomb4, and C. J. Petropoulos4 for the AMD-3100 HIV study group 1Rega Inst. for Med. Res., Katholieke Universiteit, Leuven, Belgium; 2Johns Hopkins Sch. of Med., Baltimore, MD; 3AnorMED Inc., Langley, BC, Canada; and 4ViroLogic Inc., South San Francisco, CA
| ||
| 10:30 3. | Determining the Relative Efficacy of Tenofovir DF Using Frequent Measurements of HIV-1 RNA During a Short Course of Monotherapy in Antiretroviral Drug Naïve Individuals M. Louie*1, C. Hogan1, A. Hurley1, B. Captan1, J. Flaherty2, P. Lamy2, A. Balagtas2, D. F. Coakley2, C. Chung1, D. Ho1, and M. Markowitz1 1Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY and 2Gilead Sci., Inc., Foster City, CA
| ||
| 10:45 4. | TMC125, a Next-Generation NNRTI, Demonstrates High Potency after 7 Days Therapy in Treatment-Experienced HIV-1-Infected Individuals with Phenotypic NNRTI Resistance B. Gazzard*1, A. Pozniak1, K. Arasteh2, S. Staszewski3, W. Rozenbaum4, P. Yeni5, G. van 't Klooster6 , K. De Dier6, M. Peeters6, M. P. de Béthune6, N. Graham7, and R. Pauwels6 1Chelsea and Westminster Hosp., London, UK; 2Auguste-Viktoria Clin., Berlin, Germany; 3Univ. Clin., Frankfurt, Germany; 4Hosp. Rothschild, Paris, France; 5Hosp. Bichat-Claude Bernard, Paris, France; 6Tibotec-Virco NV, Mechelen, Belgium; and 7Tibotec-Virco, Durham, NC
| ||
| 11:00 5. | TMC125 Monotherapy for 1 Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy with a 5-Drug Regimen S. Sankatsing1, G. Weverling1, G. van't Klooster2, J. Prins1, and J. Lange*1 1Univ. of Amsterdam, The Netherlands, and 2Tibotec-Virco NV, Mechelen, Belgium
| ||
| 11:15 6. | Study DPC 083-203, a Phase II Comparison of 100 and 200 mg Once-Daily DPC 083 and 2 NRTIs in Patients Failing a NNRTI-Containing Regimen N. Ruiz*1, R. Nusrat1, E. Lauenroth-Mai2, D. Berger3, C. Walworth4, L. T. Bacheler1, L. Ploughman1, P. Tsang1, D. Labriola1, R. Echols1, R. Levy1, and the DPC 083-203 Study Team 1Bristol-Myers Squibb Co., Wilmington, DE and Wallingford, CT; 2Berlin, Germany; 3Northstar Med. Ctr., Chicago, IL; 4Orange Coast Med. Group, Newport Beach, CA
| ||
| 11:30 7. | Study DPC 083-201: A Phase II Double-Blind (DB) Comparison of 3 Once Daily Doses of the NNRTI DPC 083 vs 600 mg Efavirenz (EFV) in Combination with 2 NRTIs in HIV Anti-Retroviral (ARV) Treatment-Naïve Patients N. Ruiz*1, R. Nusrat1, A. Lazzarin2, K. Arasteh3, F-D. Goebel4, S. Audagnotto5, A. Rachlis6, J. R. Arribas7, L. Ploughman1, W. Fiske1, D. Labriola1, R. Levy1, and R. Echols1 for the DPC 083-201 Study Team 1Bristol-Myers Squibb, Wilmington, DE and Wallingford, CT; 2HS Raffaele, Milan, Italy; 3Vivantes Auguste-Viktoria-Hosp, Berlin, Germany; 4Poliklinik-Medizinische, Munich, Germany; 5 Hosp. Amedeo di Savoia, Torino, Italy; 6Sunnybrook Health Sci. Ctr., ON,Canada, 7Hosp. La Paz, Madrid, Spain
| ||
| 11:45 8. | S-1360: in Vitro Activity of a New HIV-1 Integrase Inhibitor in Clinical Development T. Yoshinaga1, A. Sato1, T. Fujishita1, and T. Fujiwara*2 1Shionogi & Co. Ltd., Osaka, Japan and 2Shionogi USA, Inc., Florham Park, NJ
| ||
| 12:00 9. | Identification and Characterization of a Novel Inhibitor of HIV-1 Entry - I: Virology and Resistance P-F. Lin, B. Robinson, Y-F. Gong, K. Ricarrdi, Q. Guo, C. Deminie, R. Rose, T. Wang, N. Meanwell, Z. Yang, H. Wang, T. Zhang, and R. Colonno* Bristol-Myers Squibb Pharmaceutical Res. Inst., Wallingford, CT
| ||
| 12:15 10. | Identification and Characterization of a Novel Inhibitor of HIV-1 Entry - II: Mechanism of Action P-F. Lin, K. Guo, R. Fridell, H-T. Ho, G. Yamanaka, and R. Colonno* Bristol-Myers Squibb Pharmaceutical Res. Inst., Wallingford, CT
|
